Ongoing mumps outbreak in Israel, January to August 2017 (original) (raw)
Related papers
Vaccine, 2011
Background and aims: Despite the high national vaccination coverage, a large outbreak of mumps occurred in Israel, in 2009-2010, with onset and heavy transmission in ultraorthodox Jewish communities and further country-wide spread. We examined the sero-prevalence of mumps antibodies in the subpopulations subsequently affected by this large mumps outbreak, compared with the general population. Methods: The study was conducted in ultraorthodox Jewish communities, in Jerusalem district (N = 251), in Bnei Brak city in Tel Aviv district (N = 453), and in the general population (N = 1846), using residual sera of 1-20 year old subjects. Mumps IgG antibodies were measured using Enzygnost anti-parotitis virus IgG ELISA kit. Results: Mumps sero-positivity was significantly lower in Jerusalem: 51.8% (95% CI 51.9-61.0), and Bnei Brak: 56.5% (95% CI 45.6-57.9), than in the general population: 68.1% (95% CI 66.0-70.2). Sero-positivity increased with age, however in Jerusalem it was substantially low (46%) in the age group 10-20 years. This age group comprised a significant portion of mumps patients in the 2009-2010 outbreak. Conclusions: Low immunity levels, combined with overcrowding and social mixing, were the main predisposing factors of the enhanced epidemic transmission of mumps in the ultraorthodox Jewish communities and further country-wide spread.
Mumps outbreak in Jerusalem affecting mainly male adolescents
Eurosurveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin
From mid-September 2009 to 7 December 2009, 173 cases of mumps have been reported in the Jerusalem District. Most cases (82.1%) were male adolescents (median age 14.5 years) who are students in religious boarding schools. The majority of them (74%) are appropriately vaccinated for their age; 67% had received two doses of mumps-containing vaccine. An epidemiologic connection has been reported with visitors from New York, some of whom had recently had mumps.
2015
Mumps is a contagious disease occurring worldwide and affecting all age groups. There is no specific treatment for mumps. Mumps can be prevented by immunization using MMR. The study aimed to describe the epidemiology of the mumps outbreak, to identify the community factors favoring a mumps outbreak and to describe the public health actions taken and the lessons learned during the outbreak. This study was a cross sectional study including all notified cases of mumps in Gaza strip (GS) during the year 2013. During the year 2013, a total of 1891 clinically diagnosed mumps cases were reported with an overall incidence of 116/100000. The majority of cases 1181 (62.5%) were male. Age varied from one year to 83 years with a mean age of 13.7 years. 1708 (90.3%) of cases occurred among children aged 6 to 15 years who received only one dose of mumps vaccine. Geographically, the disease occurred mainly in Khan-Younes governorate (53.4%) followed by Mid-Zone governorate (28%). Different complic...
Characterization of Large Mumps Outbreak among Vaccinated Palestinian Refugees
Journal of Clinical Microbiology, 2009
During a large mumps virus (MuV) outbreak which occurred in the Palestinian refugee camps of the West Bank, 68.1% (2,636/3,871) of the cases were vaccinated with one dose of trivalent measles, mumps, and rubella (MMR) vaccine. Attack rates by camp ranged from less than 1 case per 1,000 people in the population to 43/1,000 (overall, 11/1,000). The outbreak lasted . To control the outbreak, a mass MMR vaccination campaign was conducted in May 2005. Evaluation of the immune status of cases (n ؍ 59) and healthy controls (n ؍ 51) revealed high levels of mumps immunoglobulin G (IgG) and a low MuV-specific IgM in clinical cases indicative of a booster immune response. This suggested a secondary rather than a primary infection due to the insufficient protection conferred by the single vaccine dose included in the vaccination program. This prediction was further confirmed by the low seroprevalence (68.6%) found in the healthy control group, which was below the threshold level required for MuV herd immunity. Mumps diagnosis was established mainly by reverse transcription-PCR in clinical samples obtained within 48 h from the onset of disease. Of the parotid fluids and nasopharyngeal aspirates analyzed, 92% were positive for MuV RNA, while only 33% of the urine samples were positive. Phylogenetic analysis of the MuV SH gene identified the outbreak strain as the H genotype, which has been in circulation worldwide at least since 1989.
Mumps outbreak in Israel's highly vaccinated society: are two doses enough?
Epidemiology and Infection
Mumps outbreaks in recent years have given rise to questions about the effectiveness of the mumps vaccine. This study examined the epidemiological data from a recent mumps outbreak in Israel and from outbreaks in other countries with high vaccination coverage, and considered whether long-established vaccination policies designed to protect against mumps are in need of revision. Of over 5000 case patients in the Israeli outbreak, half of whom were in the Jerusalem health district, nearly 40% were aged ≥15 years and, of those whose vaccination status was known, 78% had been fully vaccinated for their age - features similar to those in recent mumps outbreaks in Europe and North America. The epidemiological and laboratory evidence suggests that many previously vaccinated adolescents and young adults are now susceptible to mumps because their vaccine-based immunity has waned. Booster vaccination programmes for those at high risk of infection during mumps outbreaks - particularly those in...
Vaccine, 2011
Background: A recent mumps outbreak in Israel despite an ongoing national program of a 2-dose universal childhood vaccination policy since 1988, raised questions regarding population immunity among young adults. Objective: To assess the seroprevalence of mumps antibodies among young Israeli adults born after 1987 in order to determine evidence based vaccination policy. Methods: We conducted a seroprevalence study of mumps IgG antibodies among 441 Israeli adults born in 1988-9, based on a representative sample of sera collected upon recruitment to mandatory military service in 2007. Results: The overall seroprevalence of IgG antibody to mumps virus among 1988-9 born was 83.7%, 82.1% among males and 85.7% among females. Seroprevalence among 2007 recruits was similar to 1999 recruits (83.3%, P = 0.89) and significantly lower than 1987 recruits (94.1%, P < 0.0001). The absolute decrease between 2007 and 1987 for males was 13.1% (P < 0.0001) and for females 7.0% (P = 0.02). Seroprevalence was not significantly higher among native Israelis (84.9%) than among young adults born in the Commonwealth of Independent States (81.1%, P = 0.46) and significantly higher compared to young adults born in Western Europe or North America (68.2%, P = 0.045). Conclusions: Our findings indicate sub-optimal population seroprevalence despite a 2-dose universal childhood vaccination policy. This study allows better understanding of current mumps outbreaks in Israel and elsewhere following periods of low circulation of wild virus. These findings support mumps vaccination, even for populations and individuals that received two doses during childhood, as means for outbreak containment among young adults, especially in crowded settings, and serve as a reminder to the need for dynamic vaccination policy, supported by health promotion activities.
Declining population immunity to mumps among Israeli military recruits
Vaccine, 2006
Population-based seroepidemologic data on mumps have not been available in Israel since 1987, and the effects of mass immigration from the Commonwealth of Independent States during the 1990s have not been investigated. We conducted a seroprevalence study of mumps antibodies among 353 Israeli military recruits aged 18-19, based on a representative sample of sera collected in 1999. The overall seroprevalence rate was 83.3%, which was significantly lower than that measured in 1987 (94.1%, P < 0.001). Foreign-born subjects had substantially lower seroporevalence rates than their native Israeli counterparts (68.5% versus 86.1%, P < 0.001). Recent seroprevalence levels are below those required for herd immunity, and most likely contributed to an outbreak of mumps observed among young adults in Israel in 2005. Immigration appears to be a contributing factor to the decrease in population seroprevalence over time.
Mumps Virus Genotyping: Basis and Known Circulating Genotypes~!2009-11-20~!2009-11-26~!2010-02-16
The Open Vaccine Journal, 2010
Although mumps virus (MV) is considered antigenically monotypic, twelve different genotypes of MV based on genetic variation in the SH gene (A to L) are currently recognised by the WHO. Both dominance of a single genotype and co-circulation of different genotypes in the same geographical area, as well as temporal replacement of genotypes have been described in different countries. The different histories of genotype importation, variations in vaccine coverage and the use of different vaccine strains in each country results in a complex picture that could be the cause of the different geographical patterns of mumps virus genotype circulation observed in different countries. Lack of full cross-protection between different genotypes has been reported and has been suggested as a cause of vaccine failure, especially for vaccine strains belonging to genotype A, which is genetically distant to the remaining genotypes that include most of the currently circulating wild strains. Finally, a differential ability to invade the neural system has been suggested for some particular strains belonging to genotype D.